Product Description
An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/buparlisib)
Mechanisms of Action: PI3K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Canada, China, France, Germany, Hong Kong, Hungary, Italy, Japan, Korea, Poland, Spain, Taiwan, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Head and Neck Cancer|Squamous Cell Carcinoma
Phase 1: Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Mantle-Cell Lymphoma|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2011210034 | P3 |
Recruiting |
Squamous Cell Carcinoma|Head and Neck Cancer |
2027-12-31 |
|
| The BURAN Study | P3 |
Active, not recruiting |
Head and Neck Cancer|Squamous Cell Carcinoma |
2026-12-14 |
|
| BURAN | P3 |
Active, not recruiting |
Head and Neck Cancer |
2025-06-30 |
35% |
| AN2025H0301 | P3 |
Unknown Status |
Squamous Cell Carcinoma|Head and Neck Cancer |
2025-04-25 |